Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 641,172 shares changed hands during mid-day trading, an increase of 713% from the previous session’s volume of 78,904 shares.The stock last traded at $59.4450 and had previously closed at $58.53.
Novozymes A/S Price Performance
The company has a quick ratio of 1.00, a current ratio of 1.61 and a debt-to-equity ratio of 0.26. The company’s fifty day moving average price is $62.80 and its two-hundred day moving average price is $62.64. The company has a market cap of $27.73 billion, a price-to-earnings ratio of 42.29, a PEG ratio of 1.07 and a beta of 1.10.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.44). Novozymes A/S had a return on equity of 6.38% and a net margin of 13.96%.The company had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.22 billion. On average, equities research analysts forecast that Novozymes A/S will post 1.82 EPS for the current fiscal year.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
Featured Stories
- Five stocks we like better than Novozymes A/S
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
